Email Sign-Up
 
63 results found
Filter Filters icon
Apply

Story 10/18/18

FDA approves talazoparib for some BRCA-positive metastatic or locally advanced breast cancers

PARP inhibitor is the second approved for use in HER2-negative breast cancer in people who carry a BRCA mutation.

Story 08/21/18

MONALEESA-3 Study Findings Lead to Expanded FDA Approval of Ribociclib

A study found that combining ribociclib and fulvestrant improved progression-free survival in postmenopausal women with hormone receptor-positive metastatic breast cancer.

Story 03/21/18

CDK 4/6 Inhibitors Are Important Tools

Evelyn Robles-Rodriguez, RN, MSN, APN, AOCN, tells readers about CDK 4/6 inhibitors, a class of medicines for metastatic breast cancer that feature in an online tool from LBBC and partners.

Story 02/14/18

FDA approves pertuzumab for some early-stage HER2-positive breast cancers

Pertuzumab can be added to trastuzumab and chemotherapy for people at high risk of recurrence

Story 01/22/18

FDA approves PARP inhibitor olaparib for some BRCA-positive metastatic breast cancers

Olaparib is the first PARP inhibitor approved in breast cancer and the first medicine approved specifically for people with breast cancer and a BRCA mutation

Story 10/24/17

Pertuzumab benefits some when given with Herceptin

Adding the targeted therapy pertuzumab (Perjeta) to standard anti-HER2 treatment for early-stage, HER2-positive breast cancer resulted in more people living at least 3 years without a recurrence.

Story 10/04/17

FDA approves abemaciclib for certain HR+ metastatic breast cancers

The Food and Drug Administration has approved abemaciclib (Verzenio), both on its own and in combination with fulvestrant (Faslodex), to treat hormone receptor-positive metastatic breast cancers ...

Story 09/15/17

FDA approves neratinib for early-stage HER2-positive breast cancer

The FDA announced approval of neratinib to treat people with early-stage HER2-positive breast cancer who have completed treatment with trastuzumab (Herceptin) and chemotherapy.

Story 08/09/17

Listen to HER2: I feel ‘Dang Lucky’ to Have Been in a Clinical Trial

Kimberly Wooten spoke to LBBC about participating in a clinical trial of a HER2-targeted therapy.

Story 08/09/17

Listen to HER2: Why Are So Many Women Missing Out on Trastuzumab?

Trevor A. Jolly, MBBS, tells LBBC why trastuzumab is so important, what a recent study found about who is, and isn’t, getting treatment with trastuzumab, and what can be done about it.